++ nasdaq edit

["388"]Editas Medicine (NASDAQ:EDIT) Stock Price, News | nasdaq edit

Image Source:

nasdaq edit

Sarepta Therapeutics (NASDAQ:SRPT) signs a analysis accord acceding with Duke University beneath which it has the advantage to alone authorization the bookish acreage accompanying to the use of gene alteration technology CRISPR/Cas9 to restore dystrophin announcement in patients with Duchenne able-bodied dystrophy (DMD).

The aggregation will coact with the class of Charles A. Gersbach, Ph.D., to beforehand the belvedere and will booty the advance on analytic development.

Dr. Gerbach says, “Although early, CRISPR technology represents achievement for a ample allotment of individuals with DMD. Excising assertive exons has the abeyant to actual a majority of DMD mutations. Toward that goal, we’ve apparent in abrasion models that we can customs exons from the dystrophin gene, arch to apology of a anatomic dystrophin protein and improvements in beef strength."

Financial agreement are not disclosed.

["496.64"]EDITAS MEDICINE (NASDAQ:EDIT) Stock Chart | nasdaq edit

Image Source:

["388"]Editas Medicine (NASDAQ:EDIT) Stock Price, News | nasdaq edit

Image Source:

["679"]Is Buying Editas Medicine Incorporated (NASDAQ:EDIT) Here Good Idea? | nasdaq edit

Image Source:

["388"]What's Next for Editas Medicine Incorporated (NASDAQ:EDIT) After ... | nasdaq edit

Image Source:

["679"]Editas Medicine, Inc. (EDIT) Stock Chart - NASDAQ.com | nasdaq edit

Image Source:

["679"]Editas Medicine, Inc. (EDIT) Stock Report – NASDAQ.com - NASDAQ.com | nasdaq edit

Image Source:

["388"]Editas Medicine (NASDAQ:EDIT) Stock Price, News | nasdaq edit

Image Source:

["679"]Nasdaq Composite - Wikipedia | nasdaq edit

Image Source:

["597.52"]EDIT - Editas Medicine Inc Stock quote - CNNMoney.com | nasdaq edit

Image Source:

["388"]Editas Medicine, Inc. (NASDAQ:EDIT) Lowered to Sell at Zacks ... | nasdaq edit

Image Source:

Share on Facebook

Share on Twitter

Share on Google+

Share on LinkedIn